Clinical Trial Update: Study of KRAS Neoantigen mRNA Vaccine (ABO2102) in Patients With KRAS -Mutated Solid Tumors [EARLY_Phase 1]

View source ↗

Summary

Early-phase study evaluating ABO2102, a KRAS neoantigen mRNA vaccine, in KRAS-mutated solid tumors including pancreatic cancer; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Other Solid Tumors
• Pancreatic Cancer

Drugs mentioned

• ABO2102 (KRAS neoantigen mRNA vaccine)

Snippet

Sponsor: Ruijin Hospital | Conditions: Pancreatic Neoplasms, Other Solid Tumors | EARLY_Phase 1 | Status: RECRUITING